“How do you know if you are getting the right drugs at the right doses for treating your myeloma?”
Updates on Treatment
About admin
View all posts by admin →Subscribe
Related Posts:
- Video Updates
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib
- Levels of Uninvolved Immunoglobulins Predict Clinical Status and Progression Free Survival for Multiple Myeloma Patients
- A Phase 2 Study of Accelerated Elotuzumab Infusion, over Less than 1 Hour, in Combination with Lenalidomide and Dexamethasone, in Patients with Multiple Myeloma
James R. Berenson, MD
President and CEO - James R. Berenson, MD, Inc.
Medical & Scientific Director - Institute for Myeloma
& Bone Cancer Research (IMBCR)
Chief Executive Officer - Oncotherapeutics
Multiple myeloma (active) is the most common type plasma cell cancer. However, the following are other forms of myeloma or myeloma-related conditions:
- Monoclonal gammopathy of undetermined significance (MGUS)
- Asymptomatic (smoldering/indolent) myeloma
- solitary plasmacytoma of the bone
- Extramedullary plasmacytoma
- Light chain myeloma
- Non-secretory myeloma
- Osteosclerotic myeloma (POEMS syndrome)
- Waldenstrom macroglobulinemia
- Light chain amyloidosis
- Plasma cell leukemia
- What Is Multiple Myeloma? January 10, 2019
-
Video Updates June 26, 2018
- Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects March 5, 2017
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients March 5, 2017
- Outcomes in Multiple Myeloma Patients Evaluated March 5, 2017
- Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients February 16, 2011
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo March 19, 2011
- Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting November 23, 2011
- Understanding Myeloma News About Secondary Cancers and Clotting May 28, 2012
-
Dedication of “Determination” June 1, 2012
accelerated; elotuzumab; infusion rate; monoclonal antibody; multiple myeloma
ASCO
B-cell maturation antigen
BCMA
Biomarker
Bortezomib
bortezomib; carfilzomib; multiple myeloma; proteasome inhibitor; relapsed; refractory
Carfilzomib
Dedication
HevyLite; immunoglobulins; multiple myeloma; outcomes
IMBCR
Kyprolis
lenalidomide
monoclonal antibodies
more is not better
Multiple Myeloma
myeloma
Overall survival
Pomalyst
proteasome inhibitors
Revlimid
Secondary Cancers
TRAF6
transplant
update
December 18, 2014
Press Releases, Videos